8 minutes to Read + 7 minutes to Delve

The oral antiviral combination nirmatrelvir/ritonavir (Paxlovid) is funded for treating patients with COVID-19 in the community. This resource for prescribers and dispensing pharmacists links to Pharmac's access criteria (updated 1 October 2023) and to comprehensive drug interaction guidance.

Contributor
Eamon Duffy
31 March 2022
3 minutes to Read

Access criteria for the oral antiviral molnupiravir (Lagevrio) changed on 1 October 2023, and are different from those for the preferred antivirals, nirmatrelvir/ritonavir (Paxlovid) or remdesivir (Veklury). This resource provides a summary comparison of molnupiravir with nirmatrelvir/ritonavir.

Contributor
He Ako Hiringa, reviewed by Eamon Duffy
20 May 2022
1 minute to Read

Nirmatrelvir with ritonavir (Paxlovid), a new oral antiviral medicine for adults with COVID-19, is now available for community use. In people at higher risk of severe illness from COVID-19, treatment with Paxlovid has been shown to reduce the incidence of hospitalisation or death. However, for certain patients it will not be safe or appropriate to use Paxlovid.

Contributor
He Ako Hiringa
2 May 2022